Christian Alexander Stein

Christian Alexander Stein

Auto-generated profile, based on publicly available information

Christian Alexander Stein

Department of Hematology, Oncology, and Tumor Immunology, Charit e-Universit€ atsmedizin Berlin, Corporate Member of Freie Universit€ at Berlin and

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2022 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
CWCarlotta Welters
Carlotta Welters
MCMaría Fernanda Lammoglia Cobo
María Fernanda Lammoglia Cobo
CSChristian Alexander Stein
Christian Alexander Stein
MHMeng-Tung Hsu
Meng-Tung Hsu
AHAmin Ben Hamza
Amin Ben Hamza
LHLeo Hansmann
Leo Hansmann
Multiple myeloma is a hematologic malignancy of monoclonal plasma cells that accumulate in the bone marrow. Despite their clinical and pathophysiologic relevance, the roles of bone marrow–infiltrating T cells in treatment-naïve patients are incompletely understood. We investigated whether clonally expanded T cells (i) were detectable in multiple myeloma bone marrow, (ii) showed characteristic immune phenotypes, and (iii) whether dominant clones recognized antigens selectively presented on multiple myeloma cells. Single-cell index sorting and T-cell receptor (TCR) αβ sequencing of bone marrow T cells from 13 treatment-naïve patients showed dominant clonal expansion within CD8+ cytolytic effector compartments, and only a minority of expanded T-cell clones expressed the classic immune-checkpoint molecules PD-1, CTLA-4, or TIM-3. To identify their molecular targets, TCRs of 68 dominant bone marrow clones from five selected patients were reexpressed and incubated with multiple myeloma and non–multiple myeloma cells from corresponding patients. Only 1 of 68 TCRs recognized antigen presented on multiple myeloma cells. This TCR was HLA-C–restricted, self-peptide–specific and could be activated by multiple myeloma cells of multiple patients. The remaining dominant T-cell clones did not recognize multiple myeloma cells and were, in part, specific for antigens associated with chronic viral infections. In conclusion, we showed that dominant bone marrow T-cell clones in treatment-naïve patients rarely recognize antigens presented on multiple myeloma cells and exhibit low expression of classic immune-checkpoint molecules. Our data provide experimental context for experiences from clinical immune-checkpoint inhibition trials and will inform future T cell–dependent therapeutic strategies.


4 April 2023
Verified
Other
Open access
CWCarlotta Welters
Carlotta Welters
MCMaría Fernanda Lammoglia Cobo
María Fernanda Lammoglia Cobo
CSChristian Alexander Stein
Christian Alexander Stein
MHMeng-Tung Hsu
Meng-Tung Hsu
AHAmin Ben Hamza
Amin Ben Hamza
LHLeo Hansmann
Leo Hansmann
Multiple myeloma is a hematologic malignancy of monoclonal plasma cells that accumulate in the bone marrow. Despite their clinical and pathophysiologic relevance, the roles of bone marrow–infiltrating T cells in treatment-naïve patients are incompletely understood. We investigated whether clonally expanded T cells (i) were detectable in multiple myeloma bone marrow, (ii) showed characteristic immune phenotypes, and (iii) whether dominant clones recognized antigens selectively presented on multiple myeloma cells. Single-cell index sorting and T-cell receptor (TCR) αβ sequencing of bone marrow T cells from 13 treatment-naïve patients showed dominant clonal expansion within CD8+ cytolytic effector compartments, and only a minority of expanded T-cell clones expressed the classic immune-checkpoint molecules PD-1, CTLA-4, or TIM-3. To identify their molecular targets, TCRs of 68 dominant bone marrow clones from five selected patients were reexpressed and incubated with multiple myeloma and non–multiple myeloma cells from corresponding patients. Only 1 of 68 TCRs recognized antigen presented on multiple myeloma cells. This TCR was HLA-C–restricted, self-peptide–specific and could be activated by multiple myeloma cells of multiple patients. The remaining dominant T-cell clones did not recognize multiple myeloma cells and were, in part, specific for antigens associated with chronic viral infections. In conclusion, we showed that dominant bone marrow T-cell clones in treatment-naïve patients rarely recognize antigens presented on multiple myeloma cells and exhibit low expression of classic immune-checkpoint molecules. Our data provide experimental context for experiences from clinical immune-checkpoint inhibition trials and will inform future T cell–dependent therapeutic strategies.

4 April 2023
Verified
Other
Open access
CWCarlotta Welters
Carlotta Welters
MCMaría Fernanda Lammoglia Cobo
María Fernanda Lammoglia Cobo
CSChristian Alexander Stein
Christian Alexander Stein
MHMeng-Tung Hsu
Meng-Tung Hsu
AHAmin Ben Hamza
Amin Ben Hamza
LHLeo Hansmann
Leo Hansmann
Supplementary Data from Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma

4 April 2023
Verified
Other
Open access
CWCarlotta Welters
Carlotta Welters
MCMaría Fernanda Lammoglia Cobo
María Fernanda Lammoglia Cobo
CSChristian Alexander Stein
Christian Alexander Stein
MHMeng-Tung Hsu
Meng-Tung Hsu
AHAmin Ben Hamza
Amin Ben Hamza
LHLeo Hansmann
Leo Hansmann
Supplementary Figure from Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma

4 April 2023
Verified
Other
Open access
CWCarlotta Welters
Carlotta Welters
MCMaría Fernanda Lammoglia Cobo
María Fernanda Lammoglia Cobo
CSChristian Alexander Stein
Christian Alexander Stein
MHMeng-Tung Hsu
Meng-Tung Hsu
AHAmin Ben Hamza
Amin Ben Hamza
LHLeo Hansmann
Leo Hansmann
Supplementary Figure from Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma